BCRX
BIOCRYST PHARMACEUTICALS INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 26 ▲ BioCryst reported a transformative 2025 with $601.8 million in ORLAD…
- Mar 16 to Mar 20 ▼ 2 days of insider sells: $1.9M by 2 insiders, avg $9.39
- May 4 ▲ BioCryst entered a European licensing agreement for navenibart (HAE)…
- May 13 to May 18 ▼ 2 days of insider sells: $696.5K by 2 insiders, avg $9.45
- Jul 10 ▲ Gilbert Cisneros bought $1,001 - $15,000, last disclosed Sep 7
- Aug 5 ▲ BioCryst reported Q2 2026 GAAP EPS of $0.30, beating the $0.23 conse…
- Sep 10 ▼ RBC Capital downgrades
- Nov 4 ▲ BioCryst reported Q3 2026 total revenue of $180.3M (+13% YoY) and OR…
- Nov 4 ▲ BioCryst reported Q3 2026 total revenue of $180.3M (+13% YoY), beati…
- Nov 4 ▲ Earnings: BCRX Q3 2026 Earnings: EPS $0.14 (+63.4% vs est)
- Nov 13 FDA: BioCryst Presents New Real-World Evidence Showing Reduced…
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $2.6M.
- InstitutionsMIXED
Q3 2026: 36 added (1 new), 32 trimmed or exited. Largest new: Arrowstreet Capital, Limited Partnership $12.7M.
- AnalystsBULLISH
14 of 17 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate $0.125 → $0.100 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest +3.9% to 27.64M shares. 5.1 days to cover, ≈10.7% of shares.
- TrendDOWNTREND
9% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JUPITER ASSET MANAGEMENT LTD | DOUBLED | $33.3M |
| MORGAN STANLEY | ADD | $28.7M |
| HRT FINANCIAL LP | DOUBLED | $22.5M |
| JPMORGAN CHASE & CO | DOUBLED | $17.0M |
| Invesco Ltd. | ADD | $13.4M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | NEW | $12.7M |
| DIMENSIONAL FUND ADVISORS LP | TRIM | $11.3M |
| IMC-Chicago, LLC | TRIM | $9.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
17 analystsPrice is below the lowest target. Median implies +128%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 5, 2026 | Wedbush MAINTAIN | Outperform |
| Oct 19, 2026 | Wedbush MAINTAIN | Outperform |
| Sep 30, 2026 | JP Morgan MAINTAIN | Neutral |
| Sep 10, 2026 | RBC Capital DOWNGRADE | Sector Perform |
| Sep 8, 2026 | Needham REITERATE | Buy |
| Aug 6, 2026 | RBC Capital MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
McKee Amy E Director Aug 31, 2026 | AWARD | $6.2K |
Milne Jill C. Director Aug 31, 2026 | AWARD | $12.5K |
Stonehouse Jon P Director Aug 31, 2026 | AWARD | $6.2K |
Frank Steven Director Aug 31, 2026 | AWARD | $12.5K |
MILANO VINCENT Director Aug 31, 2026 | AWARD | $11.2K |
Frank Steven Director Jun 11, 2026 | AWARD | 15,294 sh |
Frank Steven Director Jun 11, 2026 | AWARD | 33,540 sh |
LEVIN ALAN G Director Jun 11, 2026 | AWARD | 15,294 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.10 | $0.09–$0.11 | -20.0% | $165.8M |
| Next Q | $0.17 | $0.17–$0.18 | +16.7% | $166.9M |
| Current FY | $0.86 | $0.85–$0.88 | +16.1% | $718.4M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
18 filings · 2 press releases · 5 bullish · 0 bearish · 1 mixed · 12 neutral- NEUTRAL SC 13G/ANov 16, 2026
RA Capital Management filed an amended Schedule 13G disclosing a 0.0% passive stake in BioCryst Pharmaceuticals as of September 30, 2026, down from a prior position. The filing indicates RA Capital has fully exited its holdings in BioCryst.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL PRESS RELEASENov 13, 2026
BioCryst presented two real-world studies at ACAAI 2026 showing that ORLADEYO (berotralstat)…
Monitor for any competitive shifts in HAE prophylaxis market share based on real-world evidence; navenibart interim results may influence pipeline valuation if positive.
- NEUTRAL SC 13GNov 10, 2026
State Street Corporation filed a Schedule 13G disclosing a passive 4.8% stake in BioCryst…
The reduction from above 5% to 4.8% is minor and typical for a passive index manager rebalancing. Monitor for any further filings that would indicate a continued reduction trend, but this filing…
- BULLISH 8-KNov 4, 2026
BioCryst reported Q3 2026 total revenue of $180.3M (+13% YoY) and ORLADEYO revenue of $174.8M…
ORLADEYO pellet launch and FDA approval for adolescents/adults expand the addressable market; watch Q4 for initial pellet revenue contribution and whether the CareMed inventory build normalizes as…
All BCRX filing & press-release reports (20)
- SC 13G/A reportNov 16, 2026
- PRESS-RELEASE reportNov 13, 2026
- SC 13G reportNov 10, 2026
- 8-K reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- INST-CLUSTER reportNov 2, 2026
- INST-CLUSTER reportOct 27, 2026
- PRESS-RELEASE reportOct 21, 2026
- 8-K reportAug 5, 2026
- 8-K reportJun 29, 2026
- 8-K reportJun 12, 2026
- PRESS-RELEASE reportJun 12, 2026
- CLUSTER reportMay 19, 2026
- 144 reportMay 13, 2026
- 8-K reportMay 6, 2026
- 8-K reportMay 4, 2026
- DEFA14A reportApr 23, 2026
- PRESS-RELEASE reportApr 15, 2026
- CLUSTER reportMar 16, 2026
- 8-K reportFeb 26, 2026